Information on new approvals and medication safety that rheumatologists need to know
Search results for: Certolizumab pegol
The American College of Rheumatology Helps Keep Three Biologics Off the SAD List
In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
EULAR 2013: Researchers Expand Targets for PsA, OA Therapy
Experts discuss insights in the pathogenesis of psoriatic arthritis and the role of subchondral bone in osteoarthritis
California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
Treatment for RA should involve targeting subclinical disease and reversing immune dysregulation, expert says
Dermatology Case Answer C: May
C) Tumor necrosis factor (TNF)–α-induced palmoplantar pustular psoriasis
ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
Detailed screening and treatment recommendations based on current evidence, extensive literature review.
Drug Updates
Information on new approvals and medication safety
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates
Information on New Approvals and Medication Safety
REMS Required
How will this FDA drug safety program affect rheumatology offices?
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »